#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not alone

In 2017, when Nan­jing’s Leg­end Biotech first para­chut­ed on­to AS­CO with stun­ning BC­MA CAR-T da­ta, blue­bird bio, the in­cum­bents in the field, im­me­di­ate­ly crit­i­cized their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER